Expression of RhoC and its regulators RhoGDIbeta, RhoGDIgama and their clinical importance in lung squamous cell cancer and adenocarcinoma

Abstract

Background and objective It has been proven that RhoC is known to be overexpressed in tumor. The activities of RhoC are negatively regulated by guanine nucleotide dissociation inhibitor beta,gama(GDIbeta,gama), but its role in cancer is quite limited. The purpose of the study is to investigate the expression of RhoC, RhoGDIbeta, RhoGDIgama and analyze the correlation between RhoC and RhoGDIbeta RhoGDIgama expression and clinic implication. Methods Western blot and RT-PCR were used to detect RhoC, RhoGDIbeta and RhoGDIgama protein and mRNA, respectively in 40 lung cancer tissues. Results The expression levels of RhoC, RhoGDIbeta and RhoGDIgama protein and mRNA were more remarkably higher in all tumor samples than those in the normal tissues. The expression levels of RhoC and RhoGDIgama positively correlated with clinical TNM staging, lymph node metastasis (r=0.659, P<0.05)(r=0.597, P<0.05), and the expression levels of RhoGDIβ negatively correlate with clinical TNM staging, lymph node metastasis (r=-0.621, P<0.05). Conclusion RhoC, RhoGDIbeta and RhoGDIgama are correlated with clinical TNM staging and may be correlated with lymph node metastasis of lung cancer.

Keywords

• Human RHOC protein
• Human RhoGDI beta protein
• Human RhoGDI gamma protein
• Lung neoplasms